Koya Medical to Present at Oppenheimer Healthcare Conference

The medtech innovator will highlight its portfolio and pipeline at the annual event.

Mar. 12, 2026 at 3:00pm

Koya Medical, an emerging medtech company focused on peripheral vascular health solutions, has announced that it will be presenting at the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 17, 2026. CEO Andy Doraiswamy will showcase the company's growth, commercial momentum, and progress on its clinical research pipeline.

Why it matters

Vascular diseases like chronic edema affect over 35 million Americans, highlighting the need for innovative, evidence-based treatments. Koya's presentation at the high-profile Oppenheimer conference will shine a spotlight on its efforts to address this significant unmet medical need.

The details

Koya Medical, founded in 2018 and headquartered in Dallas, is focused on developing patient-centered solutions for peripheral vascular health. The company's portfolio includes the Dayspring® non-pneumatic compression treatment for chronic edema, and it has a pipeline of additional innovations in development.

  • Koya Medical will present at 11:20am ET on Tuesday, March 17, 2026.
  • The Oppenheimer 36th Annual Healthcare MedTech & Services Conference will be held virtually from March 16-19, 2026.

The players

Koya Medical

An emerging medtech innovator advancing patient-centered solutions in peripheral vascular health.

Andy Doraiswamy

The CEO of Koya Medical who will be presenting at the Oppenheimer conference.

Got photos? Submit your photos here. ›

What’s next

Investors and analysts will be watching Koya Medical's presentation at the Oppenheimer conference to learn more about the company's growth plans and pipeline of innovative vascular health solutions.

The takeaway

Koya Medical's participation in the prestigious Oppenheimer healthcare conference underscores the company's commitment to addressing the significant unmet need in peripheral vascular diseases through its patient-centered approach and pipeline of novel treatments.